Borneol-Modified Schisandrin B Micelles Cross the Blood–Brain Barrier To Treat Alzheimer’s Disease in Aged Mice
ACS Chemical Neuroscience · 2024
DOI: 10.1021/acschemneuro.3c00625 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2024. Verfasst von Feng-Rui Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, China. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Alzheimer Disease, Camphanes, Polycyclic Compounds. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Doctoral Start-up Foundation of Liaoning Province.
Themen: Demenz
Abstract (Originalsprache)
Objective
Schisandrin B (Sch B) is a bioactive dibenzocyclooctadiene derizative that is prevalent in the fruit of Schisandra chinensis. Numerous studies have demonstrated that Sch B has a neuroprotective action by reducing oxidative stress and effectively preventing inflammation. It follows that Sch B is a potential treatment for Alzheimer's disease (AD). However, the drug's solubility, bioavailability, and lower permeability of the blood-brain barrier (BBB) can all reduce its efficacy during the therapy process. Therefore, this study constructed borneol-modified schisandrin B micelles (Bor-Sch B-Ms), which increase brain targeting by accurately delivering medications to the brain, effectively improving bioavailability. High therapeutic efficacy has been achieved at the pathological site.
Methods
Bor-Sch B-Ms were prepared using the thin film dispersion approach in this article. On the one hand, to observe the targeting effect of borneol, we constructed a blood-brain barrier (BBB) model in vitro and studied the ability of micelles to cross the BBB. On the other hand, the distribution of micelle drugs and their related pharmacological effects on neuroinflammation, oxidative stress, and neuronal damage were studied through in vivo administration in mice.
Results
In vitro studies have demonstrated that the drug uptake of bEnd.3 cells was increased by the borneol alteration on the surface of the nano micelles, implying that Bor-Sch B-Ms can promote the therapeutic effect of N2a cells. This could result in more medicines entering the BBB. In addition, in vivo studies revealed that the distribution and circulation time of medications in the brain tissue were significantly higher than those in other groups, making it more suitable for the treatment of central nervous system diseases.
Conclusion
As a novel nanodrug delivery system, borneol modified schisandrin B micelles have promising research prospects in the treatment of Alzheimer's disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, China.
- Beijing Key Laboratory of Enze Biomass Fine Chemicals, Beijing Institute of Petrochemical Technology, Qingyuan Road 19, Beijing 102617, China.
ORCID-Profile: Xue-Tao Li
Förderung
- China Postdoctoral Science Foundation
- Doctoral Start-up Foundation of Liaoning Province
Zitieren
APA
Li, F. R., Yu, Y., Du, Y. M., Kong, L., Liu, Y., Wang, J. H., Chen, M. H., Liu, M., Zhang, Z. X., Li, X. T., & Ju, R. J. (2024). Borneol-Modified Schisandrin B Micelles Cross the Blood–Brain Barrier To Treat Alzheimer’s Disease in Aged Mice. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.3c00625
Vancouver
Li FR, Yu Y, Du YM, Kong L, Liu Y, Wang JH, et al. Borneol-Modified Schisandrin B Micelles Cross the Blood–Brain Barrier To Treat Alzheimer’s Disease in Aged Mice. ACS Chemical Neuroscience. 2024. doi:10.1021/acschemneuro.3c00625
BibTeX
@article{Li2024,
author = {Li, Feng-Rui and Yu, Yang and Du, Yu-Meng and Kong, Liang and Liu, Yang and Wang, Jia-Hua and Chen, Mu-Han and Liu, Mo and Zhang, Zi-Xu and Li, Xue-Tao and Ju, Rui-Jun},
title = {Borneol-Modified Schisandrin B Micelles Cross the Blood–Brain Barrier To Treat Alzheimer’s Disease in Aged Mice},
journal = {ACS Chemical Neuroscience},
year = {2024},
doi = {10.1021/acschemneuro.3c00625}
}
EUVIMED